Ang Li
Ophthalmology · Cleveland, OHNPI 1881080703
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (34.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by NEW World Medical,inc. at 31.2% of the total. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $214.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$11K
- Nova Eye, Inc.$11K
- AbbVie$6K
- Alcon$4K
- Sight Sciences, Inc.$759
- Microsurgical Technology, Inc.$720
- plus $2K from 8 others
What the payments were for
- Consulting fees$11,93533%
- Speaking & faculty fees$12,12534%
- Travel & lodging$1,2494%
- Food & beverage$10,35329%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 48 | $11,131 |
| Nova Eye, Inc. | 5 | $10,990 |
| AbbVie(2 entities) | 23 | $6,079 |
| Alcon | 53 | $4,258 |
| Sight Sciences, Inc. | 11 | $759 |
| Microsurgical Technology, Inc. | 2 | $720 |
| Aerie Pharmaceuticals, Inc. | 5 | $419 |
| Glaukos Corporation | 8 | $388 |
| Tarsus Pharmaceuticals, Inc. | 4 | $356 |
| Oyster Point Pharma, Inc. | 1 | $223 |
| Kala Pharmaceuticals, Inc. | 1 | $120 |
| Ocular Therapeutix, Inc. | 1 | $89 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $69 |
| Bausch & Lomb Americas Inc. | 3 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Streamline$4,467
- XEN GLAUCOMA TREATMENT SYSTEM$4,099
- Kahook Dual Blade$3,265
- Ahmed Glaucoma Valve$3,265
- Clearpath$2,967
- DURYSTA$1,412
- ARGOS$1,366
- Clareon$1,249
- Centurion$1,249
- Hydrus Microstent$1,066
- Via360$786
- OMNI(R) SURGICAL SYSTEM (US)$477
- Rocklatan$337
- Streamline Surgical System$298
- Rhopressa$229
- TYRVAYA$223
- XDEMVY$134
- INVELTYS$120
How this compares
$35,663 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 108 | $56,021 |
| RocklatanNetarsudil Mesylat/Latanoprost | 72 | $44,802 |
| RhopressaNetarsudil Mesylate | 85 | $37,081 |
| VyzultaLatanoprostene Bunod | 63 | $31,047 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,165 | $22,797 |
| Brimonidine Tartrate | 698 | $22,750 |
| Latanoprost | 1,793 | $22,451 |
| Prednisolone Acetate | 382 | $18,917 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 41 | $14,762 |
| CombiganBrimonidine Tartrate/Timolol | 43 | $13,698 |
| Alphagan PBrimonidine Tartrate | 24 | $13,608 |
| XiidraLifitegrast | 12 | $13,273 |
| RestasisCyclosporine | 13 | $13,088 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 71 | $8,459 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 40 | $7,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis | $6,079 | $96,415188 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $419 | $81,882157 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $64 | $44,32075 claims |
| AlconSimbrinza | $4,258 | $14,76241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Cleveland
- Peter KaiserCleveland$1.5M
- Justis EhlersCleveland$639K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
- Yasha ModiCleveland$234K
- Faruk OrgeCleveland$158K
- Danny MammoCleveland$149K
- Douglas RheeCleveland$138K
- Jeffrey GosheCleveland$82K
- William DuppsCleveland$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.